Table 1.

Respondents’ Characteristics

	N = 74
Sex (n, %)
Male	38 (54%)
Female	33 (46%)
Age (median [IQR])	51 [44;60]
Region
Europe	49 (66%)
Northern America	19 (26%)
Other	6 (8%)
Main activity (n, %)
Clinical hematology	49 (69%)
Pathology	5 (7%)
Biological hematology	4 (6%)
Radiology or nuclear medicine	3 (4%)
Other	10 (14%)
Involvment in a dedicated MZL trial (n, %)
Primary investigator	26 (37%)
Coinvestigator	17 (24%)
Methodologist	0 (0%)
Trial steering committee	1 (1%)
Trial management group	1 (1%)
No	25 (36%)
Involvment in a trial with MZL and non-MZL patients (n, %)
Primary investigator	28 (41%)
Coinvestigator	16 (23%)
Methodologist	2 (3%)
Trial steering committee	0 (0%)
Trial management group	1 (1%)
No	34 (48%)
Involvment in MZL observational cohorts (n, %)	37 (52%)

IQR = interquartile range; MZL = marginal zone lymphoma.